Gov.hk.26 (a) (CF10) News

60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support

60 Degrees Pharmaceuticals has been awarded a contract with the United States Army Medical Materiel Development...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 424B5 - Prospectus [Rule 424(b)(5)]

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

The Tafenoquine for Babesiosis clinical trial will be conducted at three sites: Yale University, Rhode Island...

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report

Form S-3 - Registration statement under Securities Act of 1933

Form 8-K - Current report

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

WASHINGTON, July 09, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60...

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind

The efficacy and safety of tafenoquine in treating human babesiosis will be evaluated in a randomized...

60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis

With the tafenoquine for acute babesiosis orphan drug designation, 60 Degrees Pharmaceuticals now qualifies for...

Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind

60 Degrees Pharmaceuticals has entered an agreement with Tufts Medical Center to conduct a clinical trial that...

60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study

Long-term chronic fatigue syndrome (CFS) symptoms can be triggered by certain prior acute infectionsProminent...

60 Degrees Pharmaceuticals Announces First Quarter 2024 Results

Q1 2024 net product revenues increased 515% year-over-year to $105.7 thousand.Gross profit increased from...